; and (C) except as provided under paragraph (3)— (i) a copy of the form or other application, including any attachments or exhibits, submitted by each registered manufacturer requesting an opioid procurement quota; and (ii) a copy of each year-end or annual report relating to the procurement or use of opioid analgesics submitted to the Attorney General by a registered manufacturer to whom the Attorney General has issued an opioid procurement quota. (3) Upon a request by a registered manufacturer asserting that a document or information described in clause (i) or (ii) of paragraph (2)(C) is exempt from disclosure under section 552(b)(4) of title 5, United States Code, and to the extent that the Attorney General determines that the document or information is exempt from disclosure under such section 552(b)(4), the document or information may be excluded from public disclosure under paragraph (2). . (b) GAO report The Comptroller General of the United States shall submit to Congress a report that, for the 1-year period beginning on the date of enactment of this Act— (1) details— (A) the number of instances in which a registered manufacturer made a request described in section 306(i)(3) of the Controlled Substances Act, as added by subsection (a), with respect to a document or information; and (B) the number of instances in which the Attorney General determined such a document or information was exempt from disclosure under section 552(b)(4) of title 5, United States Code; and (2) evaluates the extent of the independent evaluation conducted by the Attorney General of requests described in section 306(i)(3) of the Controlled Substances Act.